Pharmabiz1d
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...
MM&M2d
AstraZeneca: New drug data, promising earnings and a $3.5B R&D investment
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
Finanznachrichten2d
AstraZeneca PLC: Dato-DXd new BLA submitted, NSQ BLA withdrawn
Patients with actionable genomic alterations were previously treated with an approved targeted therapy and platinum ... as a monotherapy and in combination with other anticancer treatments in various ...
STAT2d
AstraZeneca, Daiichi Sankyo change strategy on closely watched cancer drug
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
Business Insider2d
AstraZeneca, Daiichi Sankyo sumbit new BLA for datopotamab deruxtecan
AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application ... including an EGFR-directed therapy. The companies have voluntarily withdrawn the BLA in the US for ...
Daiichi Sankyo’s Strategic Advancements and Innovative ADC Developments Drive Buy Rating
Daiichi Sankyo Company (DSKYF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Edinburgh woman opens up on impact of 'life-changing' blood cancer diagnosis
Aileen Lamb hopes the approval of a new cancer treatment drug will give patients 'hope', after she was given the all clear ...
Pharmabiz3d
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...